Melanotan 1 Nasal Spray

Melanotan 1 is a synthetic version of the body's own hormone alpha-MSH, 13 amino acids long, with two deliberate changes: norleucine replaces methionine at position 4 and a D-phenylalanine sits at position 7. Those two building blocks make the molecule resistant to the enzymes in blood and considerably more potent than the original. It was first described in 1980 by the Arizona group that later ran the first human trials. In medicine the same compound is called afamelanotide and has been approved in the EU since 2014 as a depot implant for people with erythropoietic protoporphyria, a rare disorder in which light painfully irritates the skin.

This variant is the finished nasal spray: 10mg of Melanotan 1 dissolved in 5ml of saline (NaCl) plus 0.4ml of bacteriostatic water, 5.4ml in total, which gives 1.85mg per ml. The pump delivers 0.1ml per spray, so about 185mcg (0.19mg). On paper the bottle holds 54 sprays; after priming the pump about 50 remain. Mixing, needles and unit maths all fall away; the spray is filled fresh once you place your order and ships as an express item. If you prefer to work with the vial, the Melanotan 1 entry has the calculator.

One honest point up front: every human study of Melanotan 1 used injections under the skin or the implant. There is no published measurement of nasal dosing, neither of uptake nor of the tanning effect. This entry therefore keeps a clear line between what carries over from the injection trials and what remains experience with the spray.

This information is for research and educational purposes only. No medical advice.

Melanotan 1 binds to the melanocortin-1 receptor (MC1R) on melanocytes, the pigment cells of the skin. The receptor switches on tyrosinase, the key enzyme of melanin production, via the messenger cAMP. The cell then makes more eumelanin, the brown-black pigment. That pigment is handed on to the surrounding skin cells and the skin darkens, with less UV than would otherwise be needed. Through the same receptor, research also describes antioxidant effects and improved repair of UV damage to DNA (Minder 2017).

Unlike Melanotan II, Melanotan 1 has little pull on the MC3 and MC4 receptors in the brain. That is why the central effects Melanotan II brings are absent: no pronounced wave of nausea, no effects on libido or erections, no strong appetite suppression. When pigment is the only goal, Melanotan 1 is the more targeted tool. That stays true as a spray.

The plasma half-life after subcutaneous dosing is about 1 to 2 hours (Ugwu 1997), so the compound itself is gone from the blood quickly. The tan is not: the melanocytes keep working after the signal. In the trials skin colour peaked only 1 to 3 weeks after the last dose and then held for weeks. That is the single most important point for dosing: what you spray today, you see properly a week from now at the earliest.

The nasal lining is thin and richly supplied with blood. Whatever crosses it into the bloodstream bypasses the stomach and liver. At roughly 1,650 daltons, Melanotan 1 is a small, water-soluble peptide and in principle a candidate for this route. Even so, the rule for peptides of this size holds: only part of the dose reaches the blood, the rest is broken down by peptidases in the mucosa or drains with the secretions into the throat and is digested. For Melanotan 1 digested means inactive, because nothing was measurable in blood after oral dosing (Ugwu 1997, Minder 2017).

There is no human measurement for nasal Melanotan 1. Only the frame is known: subcutaneously the full dose arrives, orally and through the skin nothing does. The nose sits somewhere in between. Nobody has determined where. So expect one spray of nominally 185mcg to deliver clearly less active peptide than 185mcg from a syringe. Expect the tan to come more slowly or stay lighter as well. What does not help is piling on: the mucosa absorbs only a limited amount per spray. Four sprays in a row mostly run down the back of the throat.

In practice: before first use, pump 2 to 3 times into the air until a fine mist appears. Gently clear your nose first, keep your head upright, aim the nozzle slightly outward toward the nasal wall rather than at the septum, breathe in calmly, do not sniff hard. Avoid blowing your nose for 10 to 15 minutes afterwards. With two sprays use one per nostril, not both in the same side. With a cold or an irritated lining, uptake is unpredictable, so pause rather than push through.

Melanotan 1 is the best-studied tanning peptide, because as afamelanotide it went all the way to approval. The first randomised, placebo-controlled human trial came out of Arizona (Levine and colleagues, JAMA 1991): 28 healthy men received 10 subcutaneous doses over 12 days while wearing high-factor sunscreen. The skin darkened measurably in both skin-type groups, poor and good tanners alike. On placebo it did not darken at all. The tan peaked 1 to 3 weeks after the last dose.

The pharmacokinetics came from Ugwu and colleagues in 1997 (Biopharmaceutics and Drug Disposition): subcutaneously the dose arrives in full, after oral dosing nothing was detectable in blood, the plasma half-life was 0.8 to 1.7 hours. The tan on forehead, arms and neck was still there 3 weeks after the last dose. In 2004 Dorr and colleagues combined the peptide with UV-B or real sunlight in three phase 1 trials (Archives of Dermatology): irradiated skin showed 47 percent fewer sunburn cells, the tan lasted at least 3 weeks longer than with sun alone. The control group needed 50 percent more sun time for the same shade.

The largest study is by Barnetson and colleagues (Journal of Investigative Dermatology 2006) with 65 fair-skinned volunteers over three months: in sun-sensitive skin melanin rose by 41 percent, in darker skin by only 12 percent, sunburn cells after UV exposure were more than halved and UV-induced DNA damage (thymine dimers) fell by 59 percent. A review by Minder and colleagues (Clinical Pharmacokinetics 2017) sums up the clinical path: EU approval in 2014 as an implant, no late effects in volunteers 25 years after first exposure, consistently mild side effects. All of this comes from injections or the implant; for the nasal spray there are zero human measurements.

In the human trials side effects were mild: nausea, transient facial flushing with a feeling of warmth and occasional stomach upset, mostly in the first days and at doses far above the research line (Ugwu 1997, Dorr 2004). The long-term data on afamelanotide, up to 8 years with the implant and 25 years after first exposure, are unremarkable (Minder 2017). With the spray the systemic effects are likely to be weaker, because less peptide reaches the blood, but that is not guaranteed.

The visible effect is also the most common side effect: existing moles, freckles and pigment spots darken along with the skin, the face usually first. The tan can be uneven at the start. Keep an eye on your skin and have any mole that changes in shape or colour looked at by a doctor, even though Melanotan 1 is regarded as far less of a concern here than Melanotan II. For anyone with a history of melanoma or many atypical moles this peptide is off the table. There are no data for pregnancy or breastfeeding, so the same applies there. Drug interactions have not been studied for afamelanotide. Because part of the spray runs into the throat, it also reaches pigment cells in the lining of the mouth and nose; whether that changes anything there has not been studied for Melanotan 1, so a glance in the mirror does no harm.

Nasal use adds local effects: burning or tingling in the nose, sneezing, a runny nose, a bitter aftertaste and with frequent use a dry lining or slight nosebleeds. If you notice these, pause for a few days instead of pushing on. And one point that is not a side effect but the biggest risk: the tan does not reliably protect against UV damage. In the first human trial every participant wore high-factor sunscreen. That is exactly how it should stay.

The spray belongs in the fridge (2 to 8 degrees), not in the freezer and not in the door compartment where the temperature swings every time it opens. Protect it from light by leaving the bottle in its outer packaging. Store it upright so the dip tube stays in the solution. A few hours at room temperature, in the post or in a bag, do the solution no harm, but it should not sit warm for long.

Once opened, the solution keeps for several months in the fridge. Melanotan 1 is built for that: the fragile methionine of natural alpha-MSH is replaced by norleucine, which does not oxidise. There is no cysteine. The D-phenylalanine protects against enzymes. Saline is a stable medium. The 0.4ml of bacteriostatic water adds a little benzyl alcohol as a preservative. The most light-sensitive part is the tryptophan in the chain, hence the box. Beyond that, the solution's weak spot is germs, so cleanliness counts for more than cold alone. During loading the bottle is empty after 3 to 7 weeks anyway; in maintenance, use it up within about 3 months.

Wipe the nozzle with a clean tissue after each use and put the cap back on so nothing dries in and no germs migrate into the bottle. A bottle is personal, do not share it. If the solution turns gel-like, lumpy or smells different, stop using it. Slight cloudiness on its own is not a reason.